ImmuneWalk Therapeutics

Executive Summary

ImmuneWalk Therapeutics is an Israeli clinical-stage biotechnology company pioneering a novel anti-inflammatory approach through the targeting of a newly discovered adhesion checkpoint. Founded in 2020 and headquartered in Rehovot, the company’s platform focuses on controlling monocyte and neutrophil migration into inflamed tissues, a key driver of immune-mediated inflammatory diseases. Its lead candidate, IW-601, is a proprietary monoclonal antibody designed to block this checkpoint, offering a differentiated mechanism of action compared to current immunosuppressive therapies. By inhibiting the adhesion cascade early, IW-601 has the potential to treat a wide range of inflammatory conditions with improved efficacy and reduced systemic side effects. The company has advanced IW-601 into Phase 1 clinical trials, evaluating safety, tolerability, and pharmacokinetics in healthy volunteers and patients with specific inflammatory indications. While still in early stages, ImmuneWalk’s approach addresses a significant unmet need in chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, where existing biologics often lose efficacy or cause immunosuppression. The company’s scientific foundation is supported by strong preclinical data demonstrating selective blockade of pathogenic immune cell trafficking. If successful, IW-601 could become a first-in-class therapy in the immunology space, attracting interest from larger pharmaceutical partners. ImmuneWalk’s unique mechanism and early clinical validation position it as a compelling opportunity in the inflammatory disease landscape.

Upcoming Catalysts (preview)

• H2 2026Phase 1 top-line safety and PK/PD data readout85% success
• 2027Initiation of Phase 2 trial in a lead indication (e.g., rheumatoid arthritis or psoriasis)50% success
• TBDStrategic partnership or licensing deal with a larger pharmaceutical company35% success